Payment overview · 2025
General Payments
$5,788.39
76 reported records · 12 companies
Healthcare provider profile · identity verified
Wei W Bao, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CITY OF INDUSTRY, CA · NPI 1437199304
Verified facts
What the public records show
CMS Open Payments records show Wei W Bao, M.D. received $5,788.39 in general payments during 2025 across 76 reported records.
Gilead Sciences, Inc. accounted for 77.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Ozempic, Prolia, Rybelsus, Vemlidy.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 510 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Kerendia by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Nexlizet by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Vemlidy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $4,457.09 | 77.0% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $565.89 | 9.8% | 18 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $207.35 | 3.6% | 13 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $126.66 | 2.2% | 6 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $77.92 | 1.4% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $77.62 | 1.3% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $77.25 | 1.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $65.81 | 1.1% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $65.40 | 1.1% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $26.23 | 0.5% | 1 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $24.92 | 0.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.25 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,160.00 | 2 |
| Food and Beverage | $1,628.39 | 74 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Vemlidy Normalized: vemlidy |
Drug | Gilead Sciences, Inc. | $2,205.00 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $321.31 | 12 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $201.98 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $144.84 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $144.21 | 7 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $126.66 | 6 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $77.92 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $77.62 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $77.25 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $72.56 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $65.40 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.08 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $44.24 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $26.23 | 1 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $24.92 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.57 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 510 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 97 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 87 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 99 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 41 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 195 | exact normalized | Medicare Part D |
| Vemlidy vemlidy |
2025 | Vemlidy | 2024 | 132 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
41 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
510 | 81 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
87 | 14 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
132 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
99 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
195 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 972 | 206 |
| Amlodipine Besylate | Amlodipine Besylate | 586 | 118 |
| Metformin Hcl | Metformin Hcl | 538 | 105 |
| Losartan Potassium | Losartan Potassium | 537 | 115 |
| Farxiga | Dapagliflozin Propanediol | 510 | 81 |
| Alendronate Sodium | Alendronate Sodium | 333 | 77 |
| Vascepa | Icosapent Ethyl | 325 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 314 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 309 | 63 |
| Zolpidem Tartrate | Zolpidem Tartrate | 305 | 69 |
| Omeprazole | Omeprazole | 237 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 223 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 215 | 53 |
| Diclofenac Sodium | Diclofenac Sodium | 210 | 60 |
| Rybelsus | Semaglutide | 195 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 184 | 38 |
| Ezetimibe | Ezetimibe | 168 | 34 |
| Lisinopril | Lisinopril | 168 | 35 |
| Icosapent Ethyl | Icosapent Ethyl | 166 | 51 |
| Finasteride | Finasteride | 164 | 32 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 163 | 41 |
| Linzess | Linaclotide | 145 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 135 | 56 |
| Sertraline Hcl | Sertraline Hcl | 133 | 25 |
| Vemlidy | Tenofovir Alafenamide | 132 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 131 | 28 |
| Myrbetriq | Mirabegron | 107 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 107 | 19 |
| Famotidine | Famotidine | 104 | 24 |
| Azithromycin | Azithromycin | 99 | 78 |
| Ozempic | Semaglutide | 99 | 12 |
| Donepezil Hcl | Donepezil Hcl | 98 | 19 |
| Jardiance | Empagliflozin | 97 | 21 |
| Allopurinol | Allopurinol | 94 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 89 | 15 |
| Kerendia | Finerenone | 87 | 14 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 82 | 13 |
| Celecoxib | Celecoxib | 81 | 18 |
| Valsartan | Valsartan | 77 | 14 |
| Alprazolam | Alprazolam | 73 | 20 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 69 | suppressed |
| Lorazepam | Lorazepam | 68 | 15 |
| Nitroglycerin | Nitroglycerin | 64 | 19 |
| Xarelto | Rivaroxaban | 64 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 63 | 16 |
| Creon | Lipase/Protease/Amylase | 61 | 11 |
| Januvia | Sitagliptin Phosphate | 60 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 58 | suppressed |
| Simvastatin | Simvastatin | 57 | 14 |
| Gabapentin | Gabapentin | 54 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 11 |
| Cyclosporine | Cyclosporine | 52 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 49 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 48 | 28 |
| Atenolol | Atenolol | 46 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 18 |
| Repatha Sureclick | Evolocumab | 43 | suppressed |
| Ranolazine Er | Ranolazine | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 41 | suppressed |
| Prolia | Denosumab | 41 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 15 |
| Eliquis | Apixaban | 39 | suppressed |
| Hydrocortisone | Hydrocortisone | 39 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 39 | 11 |
| Fenofibrate | Fenofibrate,micronized | 37 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 36 | suppressed |
| Lansoprazole | Lansoprazole | 36 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | suppressed |
| Restasis | Cyclosporine | 35 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 34 | suppressed |
| Furosemide | Furosemide | 34 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 34 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 33 | suppressed |
| Febuxostat | Febuxostat | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Ketoconazole | Ketoconazole | 30 | 11 |
| Pregabalin | Pregabalin | 30 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 29 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | 11 |
| Ciclopirox | Ciclopirox | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Erythromycin | Erythromycin Base | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Procto-Med Hc | Hydrocortisone | 18 | suppressed |
| Edarbi | Azilsartan Medoxomil | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Seglentis | Tramadol Hcl/Celecoxib | 13 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Mitigare | Colchicine | 12 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Propylthiouracil | Propylthiouracil | 12 | suppressed |
| Quviviq | Daridorexant Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Aciphex | Rabeprazole Sodium | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 11 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 11 | suppressed |
| Naftifine Hcl | Naftifine Hcl | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Tavaborole | Tavaborole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,788.39 · 76 records | Gilead Sciences, Inc. | AIRSUPRA, BREZTRI, ENTRESTO, EVENITY, FARXIGA, JARDIANCE, KRYSTEXXA, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, PANCREAZE, PROLIA, REPATHA, Rybelsus, Tymlos, VOQUEZNA, Vemlidy, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error